Howard, Frederick M. http://orcid.org/0000-0002-6039-1141
Dolezal, James
Kochanny, Sara
Schulte, Jefree http://orcid.org/0000-0003-3920-0301
Chen, Heather
Heij, Lara http://orcid.org/0000-0002-0602-3356
Huo, Dezheng http://orcid.org/0000-0002-4041-1678
Nanda, Rita http://orcid.org/0000-0001-5248-0876
Olopade, Olufunmilayo I. http://orcid.org/0000-0002-9936-1599
Kather, Jakob N.
Cipriani, Nicole http://orcid.org/0000-0003-3092-2746
Grossman, Robert L.
Pearson, Alexander T. http://orcid.org/0000-0003-2801-7456
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (K08-DE026500)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01-CA243075)
Cancer Research Foundation
Adenoid Cystic Carcinoma Research Foundation
Article History
Received: 9 December 2020
Accepted: 1 July 2021
First Online: 20 July 2021
Competing interests
: R.N. reports relationships with Aduro, Cardinal Health, Clovis, Fujifilm, G1 Therapeutics, Genentech, Immunomedics/Gilead, Ionis, iTeos, MacroGenics, Merck, Oncosec, Pfizer, Seattle Genetics, serves on the data safety monitoring board for G1 Therapeutics, and receives research funding from Arvinas, AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics/Gilead, Merck, OBI Pharma, Odonate Therapeutics, OncoSec, Pfizer, Seattle Genetics, Taiho. O.I.O. reports relationships with CancerIQ, Tempus, and 54gene, and speaks as an Advocate for Susan G Komen and the American Cancer Society. J.N.K. reports a relationship with Owkin. A.T.P. reports a relationship with New Rhein and serves on the advisory board for Prelude Therapeutics.